Servier, Google Cloud Extend Partnership to Accelerate Drug Development with AI
Servier, an international pharmaceutical group, and Google Cloud have announced a five-year extension of their collaboration to integrate AI technologies across Servier's R&D, production, and distribution activities. This partnership aims to address challenges in drug development, which currently takes an average of 15 years, by using AI to analyze large datasets, streamline clinical trials, and optimize drug formulations.
Servier plans to leverage Google Cloud’s generative AI tools, including its Gemini large language models, to identify therapeutic targets, profile patient subpopulations, and digitalize clinical trials. Approximately 60 AI use cases have been identified, designed to enhance the probability of success, accelerate time to market, and optimize formulations, particularly for oncology and rare diseases. These AI-driven insights are expected to reduce inefficiencies across the R&D process, providing researchers and clinicians with actionable data in real-time.
See also: 17 Companies Building the Future of Drug Development on a Chip
The partnership also includes deploying AI tools across Servier’s workforce to improve efficiency while adhering to strict data security and confidentiality standards. This marks a continuation of the companies’ collaboration that began in 2022, with the shared goal of leveraging technology to bring innovative therapies to patients more effectively.
Servier’s R&D efforts benefit from over 70 active alliances and collaborations, contributing to its broader innovation ecosystem. The company’s pipeline includes candidates for solid tumors, hematological malignancies, autoimmune conditions, and neurodegenerative diseases like Parkinson’s.
Topics: AI & Digital
